Bristol Myers Squibb (BMY) Non Operating Interest Expenses (2012 - 2013)
Bristol Myers Squibb's (BMY) quarterly Non Operating Interest Expenses came in at $50.0 million in Q1 2013, up 19.05% year-over-year from $42.0 million in Q1 2012, and up 19.05% quarter-over-quarter from $42.0 million in Q1 2012.
Powered by 
Analysis
Bristol Myers Squibb (BMY) Non Operating Interest Expenses (2012 - 2013) Analysis & Trends
Bristol Myers Squibb (BMY) has reported Non Operating Interest Expenses for 2 consecutive years, with $50.0 million the latest figure, recorded in Q1 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -333.60 Mn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 23.78 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 39.74 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 582,000.00 |